ANZCTR search results

This study is examining the use of general practice point-of-care prompts to increase participation in the National Bowel Cancer Screening Program (NBCSP). Who is it for? Tasmanian general practices located in Remoteness Areas 3 and 4 may be eligible to participate and the study will apply to patients turning 50, 60 and 70 during the study timeframe. Study details Five participating general practices will have a prompt added to the electronic files of eligible patients. This message will pop-up when patients attend their consultation, and will prompt general practitioners (GPs) to encourage participation in the NBCSP. Additional resources will also be provided to the GPs in the 5 participating practices. Another 5 general practices will not receive the prompts, and will provide usual care. NBCSP participation rates will then be compared between the two groups of practices The findings from this research may have implications for the NBCSP in terms of engaging GPs in the screening invitation process, increasing participation in the program, and ultimately decreasing mortality from bowel cancer in Tasmania and nationally.

This research study aims to recruit 82 patients following an admission for chest pain or heart attack. The patients will be randomised to Colchicine 0.5mg daily or placebo for 12 months. This study aims to see how Colchicine acts on the coronary plaque. This medication is currently used for inflammatory conditions such as gout. It has a broad anti-inflammatory effect and previous research has shown that Colchicine helps to reduce adverse cardiovascular events in patients with coronary artery disease.

This study is testing a website-based intervention to encourage survivors of prostate cancer to increase their physical activity which has previously been shown to be effective in relieving cancer survivor burden Who is it for? You may be eligible for this study if you have previously been diagnosed with prostate cancer (non-metastatic) and are currently in remission. Study details Participants will be randomised (by chance) into three groups. One group will be offered the website in a stepped fashion, with modules being unlocked as the previous one is completed. The second group will be offered the complete website in a free-choice manner. The third group will be offered the website after a brief wait (4 weeks). The modules will be delivered over a 4 week period. All participants will complete a number of questionnaires about their physical activity and their experience of the website. This study aims to lay some groundwork for the use of web-based interventions targeting physical activity in prostate cancer survivors.

It is well established that physical inactivity leads to a wide range of poor health outcomes. Physical inactivity is highly prevalent in Australia, and the direct cost of physical inactivity to the Australian economy is $1.5 billion per year. Numerous physical and psychological health benefits can be reaped if more individuals engage in regular moderate intensity physical activity across all life domains, including at work. Effective, sustainable and scalable evidence-based physical activity interventions are therefore urgently needed. We propose an innovative peer-led workplace walking intervention designed to empower employees to gradually take ownership of their physical activity behaviours, thereby facilitating sustained engagement. Our research plans involve training peer leaders in the workplace, i.e. existing employees, to facilitate long-term capacity in each worksite. Our proposed research plan is based on a solid theoretical framework that involves isolating motivation effects from group-based effects on walking behaviour, and testing mediators (motivation) of intervention effects via a thorough process evaluation. We propose a pragmatic 16-week pilot cluster randomised controlled trial targeted at physically inactive employees to examine the feasibility and preliminary effects of the intervention on walking, health, well-being and work performance. Eight worksites and a total of 121 employees from these worksites will be recruited from worksites in Perth, WA. The results of the research could have direct translational potential for workplace health practice and policy with great potential for roll out across a range of work sites and sectors.

We are assessing the occurrence of bile reflux in patients who have undergone weight-loss operations. Bile reflux can predispose to oesophagitis, Barrett’s oesophagus and even oesophageal cancer. A new surgical technique has been developed and shows excellent results with regard to weight loss, remission of diabetes and safety. This technique is controversial, however, with an increased theoretical risk of bile reflux. Our study will provide additional data on the safety of weight loss operations, both generally and specifically relating to bile reflux, impacting surgical decision making in bariatric surgery. The results from our study will provide clinicians with clear evidence from which they can make informed decisions about the safety of the 'new' surgical technique. With current data showing favourable results, including improved efficacy and decreased risk of complications, increased utilisation of the technique will result in improved short-term and long-term patient outcomes. Awareness of the incidence of bile reflux post-operatively will allow clinicians to treat any reflux early, preventing or at least delaying potentially detrimental health outcomes. These interventions will translate into decreased health expenditure, providing net health and economic benefit.

The purpose of this study is to assess the pharmacokinetics, safety, and tolerability of single doses of CSL112 after intravenous administration in healthy Japanese and Caucasian subjects. Japanese subjects enrolled in the study will be assigned to Cohorts 1, 2, or 3 in a sequential manner. Caucasian subjects will be enrolled in the study and assigned to Cohort 3 only after subject matching by weight within 15% of the median weight of Japanese subjects in Cohort 3. All subjects will be randomized to treatment (CSL112 or placebo) within their cohort and within their race (Cohort 3 only).

This is a phase 1 study of a new molecule (called CEND-1) designed to enter cancer cells and increase the uptake of chemotherapy drugs. Who is it for? You may be eligible for this study if you are aged over 18 and have histologically confirmed metastatic pancreatic ductal cancer. Study details Participants in the phase 1a of the study will take the study medication CEND-1 alone initially for one week, before commencing a combination therapy with CEND-1 and the 28-day cycle of chemotherapy. Participants in the phase 1b of the study will receive the combination therapy with CEND-1 and the 28-day cycle of chemotherapy directly. Treatment may continue as long as there is perceived benefit or until disease progression. All participants will provide blood samples and undergo imaging studies. All participants will receive standard doses of chemotherapy, nabpaclitaxel and gemcitabine, approved in Australia. The primary goal of this research study is to find the correct dose of the study drug, CEND-1, that can be given alone or in combination with standard chemotherapy to patients with pancreatic cancer that has spread. Another goal is to measure the levels of CEND-1 in the blood over time. Researchers also want to learn if the study drug combinations can help to control the disease.

This study is examining brain tumour blood flow and drug uptake in patients with brain tumours originating from breast cancer. Who is it for? You may be eligible for this study if you are aged 18 or over and have a history of breast cancer, with radiologically diagnosed metastatic brain disease. Study details All participants will have an intravenous infusion containing a chemical tracer used in a PET scan. On the day of administration, plus an additional one or two occasions in the following week, participants will have a PET-MR scan. The study aims to use imaging to examine the uptake of the chemical tracer in brain metastases originating from breast cancer. It will provide new information about how treatment could be affected by unique blood flow patterns in the brain.

Advanced liver disease, or cirrhosis, is associated with increased morbidity and mortality and patients suffer frequent complications. Sarcopenia, defined as the the loss of muscle mass as well as muscle function, is among the commonest complications, with an estimated prevalence of up to 70%. Sarcopenia is independently associated with reduced survival, increased infection risk and higher rates of hospitalisation in this cohort. Despite this, little is known about how to increase muscle mass in this population. Branched chain amino acids (BCAAs) include three essential amino acids which are used as building blocks for protein and energy in muscle. In addition to being the primary energy source for skeletal muscle, they are also used to help clear toxins that build up in liver disease. Patients with cirrhosis have reduced levels of BCAAs, which is thought to be a major contributing factor that contributes to low muscle mass in these patients. Treating patients with oral BCAA supplements, in the form of a soluble powder, may improve quality of life and overall nutrition in patients with cirrhosis. However, the impact on muscle mass is unknown. Our study aims to investigate the effect of oral BCAA powdered supplements on sarcopenia in patients with cirrhosis. Our randomised trial will compare BCAAs to a control protein supplement to assess whether replacing dietary protein deficit as a whole or BCAAs specifically can influence outcomes. Our primary outcome will be an increase in muscle mass and strength in treated subjects. If we can improve sarcopenia, we anticipate we may also improve other outcomes. Therefore, our secondary outcomes of this study will be improved muscle function, hepatic encephalopathy, insulin resistance, rates of hospitalisation, health care costs, quality of life and overall mortality. Given the higher rates of infections seen in patients with sarcopenia, the second focus of our study will be on immune function through monitoring blood samples and infectious complications.

The aim of this research is to evaluate whether it is feasible to add a manual therapy technique, called Muscle Energy Technique, to a Pulmonary Rehabilitation program for people with COPD. Muscle Energy Technique is a gentle manual technique used by osteopaths, physiotherapists and massage therapists to improve joint motion and stretch the muscles. Muscle Energy Technique is commonly used in clinical practice in Australia and around the world. Recent studies have shown positive effects when Muscle Energy Technique are used with Pulmonary Rehabilitation. These benefits include improved ability to exercise. This research is important to help us understand what effects Muscle Energy Technique may have in people with COPD. Participants will be enrolled for a total of 12 weeks. Participation in the research will involve participants attending a Pulmonary Rehabilitation program twice per week for 8 weeks. In weeks 1, 2 and 3 and 5, 6 and 7 they will also receive a Muscle Energy Technique treatment before the Pulmonary Rehabilitation session once per week. These will be conducted in the physiotherapy department at Austin Health. In week 12 participants will receive a follow up phone call from the researcher. The follow up phone call in week 12 should take no longer than 10 minutes.